Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Cerebral infarction is the second leading cause of death and the third most common cause of disability. The use of anti-platelet aggregation drugs is prone to bleeding, liver and kidney damage, gastrointestinal reactions, and is not suitable for patients to take for a long time. Xuesaitong oral preparations (XSTOP), a traditional Chinese medicine formula, has shown therapeutic effect on treating cerebral infarction based on the clinical practice and pharmacological mechanism.AIM OF THE STUDY: The study aims to evaluate the effectiveness and safety of XSTOP combined with conventional treatment (CT) in treatment of acute cerebral infarction (ACI), and to provide the reliable evidence for clinical application.MATERIALS AND METHODS: We performed a literature search in Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, PubMed, EMBASE, Cochrane Library and Web of Science from their inceptions to August 2021. Systematic searches for randomized controlled trials (RCTs) of XSTOP in treatment of ACI. Odds ratio (OR) or mean difference (MD) with their 95% confidence interval was calculated between with and without XSTOP therapy. Cochrane risk of bias tool was used to evaluate the methodological quality of the included trials.RESULTS: Eight RCTs involving 827 patients were included in this meta-analysis. By comparing XSTOP plus conventional treatment with conventional treatment alone, the meta-analysis gave the following results: (1) Total effective rate (OR = 4.53, 95% CI[2.85, 7.19], P < 0.0001); (2) National Institutes of Health Stroke Scale (NIHSS) score (MD = -3.22, 95% CI[-4.52, -1.92], P<0.00001); (3) Plasma viscosity (PV) (MD = -0.74, 95%CI [-0.96, -0.51], P<0.00001), hole blood high-cut viscosity (HBV) (MD = -0.63, 95%CI [-0.73, -0.53], P = 0.84), whole blood low-cut viscosity (LBV) (MD = -0.37, 95%CI [-0.56, -0.19], P = 0.96), fibrinogen (FIB) (MD = -23.78, 95%CI [-28.57, -18.99], P = 1.00), hematocrit (Hct) (MD = -2.76, 95%CI [-3.16, -2.36], P = 0.96); (4) China Stroke Scale (CSS) score (MD = -6.53, 95% CI[-9.07, -3.99], P<0.00001); (5) No significant adverse reactions were reported; (6) The evidence was downgraded to "very low" quality, according to GRADE system.CONCLUSION: XSTOP plus CT is conditional recommended to improve the total effective rate, NIHSS score, PV, CSS score, and no serious adverse reactions were noted. The GRADE assessment indicates that the overall certainty quality of evidence is very low. Further large-scale, well-designed and high-quality RCTs are needed to confirm the positive results. As all studies included were conducted in China. It is unclear if the findings of this meta-analysis could be generalized to other populations.

Effect of Xuesaitong soft capsule on hemorrheology and in auxiliarily treating patients with acute cerebral infarction

Effect and safety of rt-PA combined with Hydroxyethyl starch in the treatment of acute cerebral infarction

Xueshuantong Improves Cerebral Blood Perfusion in Elderly Patients with Lacunar Infarction.

Treating 39 Patients of Acute Cerebral Infarction by TongXinLuo Capsule and Western Medicine

Efficacy and Safety of Xueshuantong Injection on Acute Cerebral Infarction: Clinical Evidence and GRADE Assessment

Xi-Xian-Tong-Shuan Capsule Alleviates Vascular Cognitive Impairment in Chronic Cerebral Hypoperfusion Rats by Promoting White Matter Repair, Reducing Neuronal Loss, and Inhibiting the Expression of Pro-Inflammatory Factors.

Xuesaitong oral preparation as adjuvant therapy for treating acute cerebral infarction: A systematic review and meta-analysis of randomized controlled trials

Xuesaitong injection as one adjuvant treatment of acute cerebral infarction: a systematic review and meta-analysis

The Efficacy and Safety of the Xuesaitong Soft Capsule in the Treatment of Patients with Ischemic Stroke: Systematic Review and Meta-Analysis

Abstract TMP1: Xuesaitong Improves The Prognosis Of Patients With Ischemic Stroke

Effects of Puerarin with Aspirin on the Markers of Damaged Vascular Endothelial Cells in Patients with Acute Cerebral Infarction

Effects of Xuesaitong on blood rheology of patients with cerebral infarction

Efficacy of Getong Tongluo Capsule plus Clopidogrel hydrogen sulfate tablets Therapy Assisted by Home Rehabilitation Guidance in Convalescents from Cerebral Infarction

Improvement of Hematoma Absorption and Neurological Function in Patients with Acute Intracerebral Hemorrhage Treated with Xueshuantong

Observation of the Result of Tongxinluo Capsule for the Treatment of Acute Cerebral Infarction and Analysis of Its Mechanism

Effect of the Xingling dispersible tablet on carotid atherosclerotic and inflammatory factors in patients with cerebral infarction

Clinical observation of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection combined with atorvastatin in treatment of acute cerebral infarction

Efficacy of Fuyuan Xingshen Decoction Combined with Butylphthalide Sodium Chloride Injection in the Treatment of Acute Cerebral Infarction and Its Effect on Hemodynamics

Xuesaitong Injection (lyophilized) Combined with Aspirin and Clopidogrel Protect Against Focal Cerebral Ischemic/reperfusion Injury in Rats by Suppressing Oxidative Stress and Inflammation and Regulating the NOX2/IL-6/STAT3 Pathway

[Clinical Trial on Treatment of Acute Cerebral Infarction with TCM Treatment According to Syndrome Differentiation Combining Western Medicine by Staging].

Xuesaitong injection (lyophilized) combined with aspirin and clopidogrel protect against focal cerebral ischemic/reperfusion injury in rats by suppressing oxidative stress and inflammation and regulating the NOX2/IL-6/STAT3 pathway.